Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody designed to neutralize proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting the interaction between PCSK9 and the low-density lipoprotein receptor (LDLR), Frovocimab facilitates the normal proteolytic processing of PCSK9 without disrupting its binding, thereby maintaining cholesterol homeostasis. This antibody is pivotal for research focused on lipid metabolism and cardiovascular diseases, offering potential insights into the regulation of cholesterol levels and the mechanisms of atherosclerosis.
Frovocimab (LY 3015014) is a humanized IgG4 monoclonal antibody designed to neutralize proprotein convertase subtilisin/kexin type 9 (PCSK9). By inhibiting the interaction between PCSK9 and the low-density lipoprotein receptor (LDLR), Frovocimab facilitates the normal proteolytic processing of PCSK9 without disrupting its binding, thereby maintaining cholesterol homeostasis. This antibody is pivotal for research focused on lipid metabolism and cardiovascular diseases, offering potential insights into the regulation of cholesterol levels and the mechanisms of atherosclerosis.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
